An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Breast Cancer
Interventions: OTHER: None (Observational Study)
Sponsor: AstraZeneca